Ashish Saxena, MD, PhD, is an associate professor of clinical medicine at Weill Cornell Medical College and an assistant attending physician at NewYork-Presbyterian Hospital
Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the potential future utility of PD-L1 expression as a biomarker in EGFR-mutated NSCLC.
Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.
Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, note data from a study of PD-L1 expression as a marker of response to TKIs in EGFR-mutated NSCLC.
Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the role for PD-L1 expression as a biomarker for treatment response in EGFR-mutant NSCLC.
Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.
Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the possibility of expanding the use of supportive care regimens to reduce the effects of myelosuppression in patients with SCLC.
Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.
Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.
Jorge Nieva, MD, and Ashish Saxena, MD, PhD, talk about factors to consider when weighing the risk/benefit ratio associated with the use of cyclin-dependent kinase 4/6 inhibition.
Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the impact of chemotherapy-induced myelosuppression on patients with SCLC.
Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses the future of next-generation ALK inhibitors in non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses available next-generation ALK inhibitors in non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses the importance of initial therapy selection in ALK-positive non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.
Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.
June 21st 2023
December 12th 2019
